novartis - dofaq.co
노바티스, 희귀질환약 비조이스 과립제형 FDA 추가 승인
뉴스더보이스헬스케어 - 29 Apr 2024
노바티스, 희귀질환약 비조이스 과립제형 FDA 추가 승인 ...
노바티스, 골수섬유증 약 안전성 문제에도 “모포시스 인수”
메디소비자뉴스 - 29 Apr 2024
노바티스, 골수섬유증 약 안전성 문제에도 “모포시스 인수” ...
Novartis pays PeptiDream $180M as radiopharma big bang continues
Fierce Biotech - 30 Apr 2024
Novartis pays PeptiDream $180M as radiopharma big bang continues ...
[데일리팜] 노바티스 일라리스, 국내허가 9년만에 급여 청신호
데일리팜 - 28 Apr 2024
[데일리팜] 노바티스 일라리스, 국내허가 9년만에 급여 청신호 ...
PeptiDream Expands Peptide Discovery Collaboration With Novartis
Contract Pharma - 30 Apr 2024
PeptiDream Expands Peptide Discovery Collaboration With Novartis ...
Morphosys says takeover by Novartis on course after report of drug safety concern
Reuters - 29 Apr 2024
Morphosys says takeover by Novartis on course after report of drug safety concern ...
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition
STAT - 28 Apr 2024
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition ...
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
Business Wire - 30 Apr 2024
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis ...
Research and development
Novartis - 08 Feb 2024
Research and development ...
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
BioSpace - 29 Apr 2024
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT ...
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Fierce Pharma - 26 Apr 2024
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia ...
Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs
CNBC - 23 Apr 2024
Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs ...
Novartis reports 25% increase in net income in Q1 2024
Pharmaceutical Technology - 24 Apr 2024
Novartis reports 25% increase in net income in Q1 2024 ...
한국노바티스 ‘일라리스’, 급여 등재 시동
메디소비자뉴스 - 28 Apr 2024
한국노바티스 ‘일라리스’, 급여 등재 시동 ...
Novartis nominates ex-BMS chief Giovanni Caforio as its next chair
Fierce Pharma - 23 Apr 2024
Novartis nominates ex-BMS chief Giovanni Caforio as its next chair ...
Research disease areas
Novartis - 08 Feb 2024
Research disease areas ...
한국노바티스 "'일라리스', 근거자료 제출 조건부 '급여 적정성' 수용"
메디소비자뉴스 - 26 Apr 2024
한국노바티스 "'일라리스', 근거자료 제출 조건부 '급여 적정성' 수용" ...
Novartis in Society Integrated Report
Novartis - 31 Jan 2024
Novartis in Society Integrated Report ...
Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs
Fierce Pharma - 23 Apr 2024
Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs ...